A case-control study was undertaken to investigate the status of platelet monoamine oxidase-B (MAO-B) activity in Indian cases of idiopathic Parkinson's disease. A significant increase in the activity of platelet MAO-B was observed in Parkinson's cases (n = 26) as compared to controls (n = 26). No significant change in the activity of the enzyme was observed while the data was analysed with respect to age, sex and duration of disease. A trend of decrease in platelet MAO-B activity was observed in Parkinson's cases with respect to stage although the change was not significant. No correlation in platelet MAO-B activity was observed with respect to age and sex in the control subjects. Parkinson's cases treated with L-DOPA and MAO-B inhibitor e...
The level of platelet monoamine oxidase (MAO) has been found to be abnormally low in certain types o...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson’s disease (PD)....
An increase in platelet monoamine oxidase (MAO) B activity in drug-free parkinsonians (n = 6) compar...
Monoamine oxidase type B (MAO-B) and superoxide dismutase (SOD) are two enzyme systems that are pote...
Platelet monoamine oxidase activity levels have been evaluated in several neuropsychiatric disorders...
We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa tr...
SUMMARY The most readily available source of monoamine oxidase in man is the platelet, although only...
Oxidative stress plays a central role in the pathogenesis of Parkinson's disease (PD). L-DOPA, the g...
SUMMARY The possibility that genetically determined abnormalities in the monoamine oxidase of certai...
Idiopathic Parkinson\u27s disease (PD) is an age dependent, neurodegenerative disorder and is predom...
Activity of mitochondrial enzyme complex I (NADH-ubiquinone oxidoreductase) is reduced in the substa...
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitor...
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson'...
Thesis (Ph.D. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2008.Very li...
The level of platelet monoamine oxidase (MAO) has been found to be abnormally low in certain types o...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson’s disease (PD)....
An increase in platelet monoamine oxidase (MAO) B activity in drug-free parkinsonians (n = 6) compar...
Monoamine oxidase type B (MAO-B) and superoxide dismutase (SOD) are two enzyme systems that are pote...
Platelet monoamine oxidase activity levels have been evaluated in several neuropsychiatric disorders...
We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa tr...
SUMMARY The most readily available source of monoamine oxidase in man is the platelet, although only...
Oxidative stress plays a central role in the pathogenesis of Parkinson's disease (PD). L-DOPA, the g...
SUMMARY The possibility that genetically determined abnormalities in the monoamine oxidase of certai...
Idiopathic Parkinson\u27s disease (PD) is an age dependent, neurodegenerative disorder and is predom...
Activity of mitochondrial enzyme complex I (NADH-ubiquinone oxidoreductase) is reduced in the substa...
Patients with Parkinson’s disease receive selective irreversible monoamine oxidase (MAO)-B inhibitor...
Monoamine oxidase-B (MAO-B) inhibitors are commonly used for the symptomatic treatment of Parkinson'...
Thesis (Ph.D. (Pharmaceutical Chemistry))--North-West University, Potchefstroom Campus, 2008.Very li...
The level of platelet monoamine oxidase (MAO) has been found to be abnormally low in certain types o...
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are use...
Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson’s disease (PD)....